Reossification and Prognosis Following Radiotherapy With/without Surgery for Spinal Solitary Plasmacytoma of the Bone: a Retrospective Study of 39 Patients.
Hanqiang Ouyang,Songbo Han,Liang Jiang,Hongqing Zhuang,Shaomin Yang,Yan Liu,Lihua Zhang,Xiaoguang Liu,Feng Wei,Keyuan Chen,Siyu Zhou,Zhongjun Liu
DOI: https://doi.org/10.1016/j.spinee.2019.09.018
IF: 4.297
2020-01-01
The Spine Journal
Abstract:BACKGROUND CONTEXT: Solitary plasmacytoma of bone (SPB) can progress to multiple myeloma (MM). Little attention has been paid to the reossification findings on computed tomography (CT) and their correlation with prognosis after radiotherapy with/without surgery. PURPOSE: To evaluate reossification after radiotherapy and prognostic factors of spinal SPB using single-center data. STUDY DESIGN: Retrospective observational study. PATIENT SAMPLE: Patients who had spinal SPB and received radiotherapy with/without surgery, without chemotherapy, denosumab or zoledronic acid. OUTCOME MEASURES: MM progression rate, mortality rate, and reossification rate at 12 months. METHODS: This retrospective clinical review included 39 patients who underwent radiotherapy as first-line treatment for SPB in the spine. External radiation was divided into 20-25 fractions with a total dose of 35-46 Gy. At the 12-month follow-up after the index radiotherapy, significant and mild reossification, defined as bone formation with >= 30% or 0%-30% increase, respectively, in bony area based on increase in CT values were documented, along with progressive disease, which was a decrease in bony area with lesion enlargement. This study was funded by AO Foundation, AOSpine (AOSDIA2019-026) (CHF45,000), Peking University Medicine Seed Fund for Interdisciplinary Research (BMU2018MX022) ((sic)40,000), and Peking University Third Hospital (No. Y71508-01) ((sic)400,000). RESULTS: Twenty-six men and 13 women (mean age, 51.5 years) were included. Solitary plasmacytomas were located in the cervical, thoracic, and lumbar vertebrae in 16, 17, and 6 patients, respectively. The mean clinical follow-up period after treatment was 72 (range 12-216) months. Sixteen patients (41.0%) had significant reossification after radiotherapy, 21 (53.8%) showed mild reossification, and 2 (5.2%) had progressive bony destruction (after 7 and 23 months, respectively). There were no significant differences in age among the three groups (p=.127). At a mean follow-up of 37 (range 6-90) months after radiosurgery, 14 (35.8%) patients developed MM, including 9 patients who died at a mean duration of 55 (range 19-102) months. In the significant reossification group, only 1 patient (6.3%, 1 of 16) had MM progression 82 months after treatment (p=.044). In the mild reossification group, 56.5% (13 of 23) of patients had MM progression. The significant reossification rates of the radiotherapy dose groups of < 40 Gy and >= 40 Gy were 35.7% and 44% (p=.614), respectively. In the univariate analysis, age >= 65 years (p<.001), tumor >= 5 cm (p=.009), Spinal Instability Neoplastic Score scores >= 11.5 (p=.040), radiotherapy (RT) combined with surgery (p<.001), and progression to MM (p=.007) were the independent prognostic factors for overall survival; whereas, age > 44 years (p=.045) and RT combined with surgery (p<.001) were for multiple myeloma-free survival. In the multivariate analyses, age > 65 years (p=.004) and progression to MM (p=.007) were the unfavorable independent factors for overall survival, whereas RT combined with surgery (p=.004) was the only factor for multiple myeloma-free survival. CONCLUSIONS: In patients with spinal SPB, 41.0% lesions showed significant reossification after radiotherapy. Patients with significant reossification had a better prognosis with less possibility of MM progression. Radiotherapy may be a safe and effective treatment choice for spinal SPB; more attention should be paid to reossification. (C) 2019 Elsevier Inc. All rights reserved.